- Home
- NEO vs NXP Comparison
NEO vs NXP Comparison
Compare NEO & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEO
- NXP
- Stock Information
- Founded
- NEO 2001
- NXP 1992
- Country
- NEO United States
- NXP United States
- Employees
- NEO N/A
- NXP N/A
- Industry
- NEO Precision Instruments
- NXP Trusts Except Educational Religious and Charitable
- Sector
- NEO Health Care
- NXP Finance
- Exchange
- NEO Nasdaq
- NXP Nasdaq
- Market Cap
- NEO 709.2M
- NXP 699.7M
- IPO Year
- NEO 1999
- NXP N/A
- Fundamental
- Price
- NEO $6.61
- NXP $13.92
- Analyst Decision
- NEO Buy
- NXP
- Analyst Count
- NEO 8
- NXP 0
- Target Price
- NEO $12.00
- NXP N/A
- AVG Volume (30 Days)
- NEO 3.0M
- NXP 70.0K
- Earning Date
- NEO 07-29-2025
- NXP 01-01-0001
- Dividend Yield
- NEO N/A
- NXP 4.04%
- EPS Growth
- NEO N/A
- NXP N/A
- EPS
- NEO N/A
- NXP 0.54
- Revenue
- NEO $689,189,000.00
- NXP N/A
- Revenue This Year
- NEO $13.83
- NXP N/A
- Revenue Next Year
- NEO $11.35
- NXP N/A
- P/E Ratio
- NEO N/A
- NXP $26.81
- Revenue Growth
- NEO 9.70
- NXP N/A
- 52 Week Low
- NEO $4.72
- NXP $12.91
- 52 Week High
- NEO $19.12
- NXP $14.89
- Technical
- Relative Strength Index (RSI)
- NEO 58.15
- NXP 48.33
- Support Level
- NEO $5.94
- NXP $13.90
- Resistance Level
- NEO $6.35
- NXP $14.01
- Average True Range (ATR)
- NEO 0.26
- NXP 0.07
- MACD
- NEO 0.12
- NXP -0.00
- Stochastic Oscillator
- NEO 99.20
- NXP 15.86
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.